Cargando…
Apixaban Use in Patients with Protein C and S Deficiency: A Case Series and Review of Literature
BACKGROUND: Historically, warfarin was the mainstay anticoagulant agent to manage patients presenting with thrombotic disorders caused by Protein C or S deficiency. Several direct oral anticoagulants (DOACs) were introduced over the past decade. They showed superiority over warfarin in patients with...
Autores principales: | Al Sulaiman, Khalid, Alsuwayyid, Faisal, Alrashidi, Abdulrahman, Alhijris, Mohammed, Almutairi, Faisal, Alharthi, Fahad, Abu Esba, Laila Carolina, Aljuhani, Ohoud, Badreldin, Hisham A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901412/ https://www.ncbi.nlm.nih.gov/pubmed/35264892 http://dx.doi.org/10.2147/JBM.S344083 |
Ejemplares similares
-
Evaluation of Apixaban in Patients With Antiphospholipid Syndrome: A Case Series and Review of Literature
por: Al Sulaiman, Khalid, et al.
Publicado: (2022) -
Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study
por: Al Sulaiman, Khalid, et al.
Publicado: (2022) -
What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies
por: Badreldin, Hisham A., et al.
Publicado: (2022) -
Practical Guide for Anticoagulant and Antiplatelet Reversal in Clinical Practice
por: Aldhaeefi, Mohammed, et al.
Publicado: (2023) -
Clinical Pharmacy Faculty Provision of Direct Patient Care, Challenges, and Opportunities
por: Korayem, Ghazwa B., et al.
Publicado: (2023)